NYSE:IMVIMV Stock Price, Forecast & News

IMV's stock was trading at $2.38 on March 11th, 2020 when Coronavirus (COVID-19) reached pandemic status according to the World Health Organization (WHO). Since then, IMV stock has increased by 23.9% and is now trading at $2.95. View which stocks have been most impacted by Coronavirus.

7 Wall Street analysts have issued "buy," "hold," and "sell" ratings for IMV in the last year. There are currently 2 hold ratings and 5 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View analyst ratings for IMV.

IMV is scheduled to release its next quarterly earnings announcement on Thursday, August 13th 2020. View our earnings forecast for IMV.

Imv Inc (NYSE:IMV) issued its earnings results on Friday, May, 15th. The company reported ($0.14) earnings per share (EPS) for the quarter, missing the Thomson Reuters' consensus estimate of ($0.11) by $0.03. The company earned $0.05 million during the quarter, compared to the consensus estimate of $0.04 million. View IMV's earnings history.

7 brokerages have issued 1-year price objectives for IMV's shares. Their forecasts range from $3.00 to $13.00. On average, they expect IMV's share price to reach $7.42 in the next year. This suggests a possible upside of 151.4% from the stock's current price. View analysts' price targets for IMV.

News headlines about IMV stock have trended very negative this week, according to InfoTrie Sentiment Analysis. The research firm scores the sentiment of media coverage by monitoring more than six thousand news and blog sources in real-time. The firm ranks coverage of publicly-traded companies on a scale of -5 to 5, with scores nearest to five being the most favorable. IMV earned a media sentiment score of -3.2 on InfoTrie's scale. They also gave news coverage about the company a news buzz of 0.0 out of 10, indicating that recent media coverage is extremely unlikely to have an effect on the stock's share price in the next few days. View the latest news about IMV.

Some companies that are related to IMV include Aptose Biosciences (APS), Oxford BioMedica (OXB), CEL-SCI (CVM), Cel-Sci (CVM), Paradigm Biopharmaceuticals (PAR), SIGA Technologies (SIGA), Biotest (BIO), Neptune Wellness Solutions (NEPT), TELIX Pharmaceutical (TLX), Starpharma (SPL), Silence Therapeutics (SLN), Altimmune (ALT), iShares Diversified Alternatives Trust (ALT), ProMetic Life Sciences (PLI) and Pfenex (PFNX). View all competitors.

Based on aggregate information from My MarketBeat watchlists, some companies that other IMV investors own include Inovio Pharmaceuticals (INO), Matinas BioPharma (MTNB), Gilead Sciences (GILD), Nokia Oyj (NOK), SCYNEXIS (SCYX), VBI Vaccines (VBIV), Cidara Therapeutics (CDTX), Vaxart (VXRT), ADMA Biologics (ADMA) and Amplify Energy (AMPY).

IMV trades on the New York Stock Exchange (NYSE) under the ticker symbol "IMV."

Shares of IMV can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

One share of IMV stock can currently be purchased for approximately $2.95.

IMV has a market capitalization of $182.03 million.

The company can be reached via phone at (902) 492-1819.